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Is there a need to prevent hepatocellular
carcinoma?
Hepatocellular carcinoma (HCC) is considered to be
one of the major malignant diseases in the world today.
Among the reasons for this are two that are especially
relevant in considering the need to prevent this tumor.
The first is the high incidence of HCC, and the second
its grave prognosis.
HCC is now the fifth most common global cancer
(fifth in males and eighth in females) if colon and rectal
cancers and mouth and pharyngeal cancers are
grouped together [1,2]. Moreover, it is either the most
common tumor or among the three most common
tumors in many of the most populous regions of the
world [1–3]. Assuming that HCC constitutes 85% or
more of primary liver cancers, 480 000 new cases of
HCC were estimated to occur worldwide in the year
2000, and the tumor accounted for 4.8% of all new
human cancers (6.4% among men and 3.0% among
women) [1]. The incidence of HCC differs appreciably
in different geographical regions, with 80% of cases
occurring in low-income countries in sub-Saharan
Africa or low-income countries (or occasionally coun-
tries that were low-income until relatively recently) in
eastern or south-eastern Asia and the Pacific islands
[1–3].
In addition to its high incidence, HCC carries a
particularly poor prognosis, even more so in popula-
tions in which the tumor is very common. HCC ranks
fourth in annual global cancer mortality rates [1,4]. In
low-income countries with a high incidence of HCC,
the tumor is responsible for as much as two-thirds of
cancer deaths [1], and its annual mortality rate is
virtually identical to its annual incidence [3,4]. For
example, in a year in which 371 400 new cases of HCC
were estimated to have occurred, 363 000 patients died
as a result of the tumor, giving an annual fatality ratio of
0.97 [3]. Because of the often rapid growth rate of
HCC, especially in Black African and Chinese popu-
lations, and the absence of symptoms during the early
stages of the disease, the tumor is frequently advanced
when the patient is first seen. Moreover, when symp-
tomatic, HCC is seldom amenable to, and has a high
recurrence rate after, resection or ablation by other
means and is almost always refractory to nonoperative
forms of treatment.
Thus, it is obvious that so prevalent is HCC, parti-
cularly in populous low-income countries, and so poor
are the results of treatment when the tumor is symp-
tomatic, that prevention of HCC is an urgent priority.
Definition of cancer prevention
Cancer prevention can be attempted at three levels [5].
 Primary prevention is preventing an etiological
agent from initiating the carcinogenic process.
This is the premier strategy and is achieved by
eliminating, avoiding, or neutralizing the carci-
nogen, or by stopping the in vivo conversion of a
precarcinogen into a carcinogen.
 Secondary prevention is interfering with the
metabolism of a carcinogen, or preventing it from
reaching its target or interacting with tissue
nucleophiles, especially DNA.
 Tertiary prevention is preventing precancerous
lesions from progressing to cancer.
The term ‘secondary prevention’ has in the past been
loosely used to refer to the detection and surgical
resection or ablation by other means of small pre-
symptomatic tumors in population screening or case
detection and surveillance programs. This intervention
is a commendable attempt to improve the dismal
prognosis of patients with symptomatic HCC by early
diagnosis and treatment of the tumor, but it is not, by
definition, prevention.
Primary prevention of a tumor depends upon
knowing the risk factor or factors for the tumor,
and secondary and tertiary prevention require, in
addition, knowledge of the mechanisms involved in its
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pathogenesis. HCC is multifactorial in etiology and has
a complex multi-step pathogenesis. A number of major
and minor causal associations have been identified,
although less is known about the genesis of the tumor.
Risk factors for hepatocellular carcinoma
The geographically most widely distributed of the
major causal associations of HCC are chronic hepatitis
B (HBV) and C virus (HCV) infections and cirrhosis,
whatever its cause. Other risk factors are important in
certain geographical regions only: dietary exposure to
aflatoxins in parts of sub-Saharan Africa, China and
Taiwan; dietary iron overload in Black Africans in parts
of sub-Saharan Africa; and ditch, pond or river water
contaminated by blue-green algae that produce
microcystins in parts of China. Minor risk factors are
oral contraceptive steroids, cigarette smoking, a
number of inherited metabolic diseases (the most
common of which is hereditary hemochromatosis),
insulin resistance, and membranous obstruction of the
inferior vena cava. The main thrust of any prevention
program should be directed against the more impor-
tant etiological forms of HCC.
Hepatitis B virus
Chronic HBV infection is the predominant global
cause of HCC and accounts for as much as 80% of the
tumor in regions with a very high incidence of HCC.
More than 2 billion of the world’s population are
estimated to show serological evidence of present or
past HBV infection, and some 385 million (approxi-
mately 6% of the global population) are chronic
carriers of the virus. Of the latter, 25% or more will
develop HCC [1–3] (in hyperendemic regions of the
virus, such as Taiwan, more than 40% will die from
HCC, cirrhosis, or both diseases [6]). HBV is today
considered to be (with tobacco) the most important
environmental carcinogen to which humans are
exposed. In those geographical regions where the virus
is hyperendemic, with carrier rates as high as 15% or
more, and the incidence of HCC very high (in eastern
and south-eastern Asia, some of the Pacific islands, and
sub-Saharan Africa), the infection is predominantly
acquired in infancy or early childhood. The main route
of infection in Chinese populations is perinatal, with
fewer infections occurring later by horizontal spread of
the virus [7]. In contrast, relatively few infections in
Black African populations occur as a result of perinatal
transmission, and most of the infections are acquired a
little later by horizontal spread [8]. The exact routes of
horizontal transmission of HBV between young chil-
dren are uncertain. HBV infections acquired this early
in life have an 80–90% chance of becoming chronic,
and it is these early-onset carriers that are at extremely
high risk of HCC development, with lifetime relative
risks as high as 100 or more [6]. The risk of malignant
transformation is greater when cirrhosis is present.
Although it is known that HBV may be both directly
and indirectly carcinogenic (the latter by causing
chronic necroinflammatory hepatic disease), much
remains to be learnt about the precise mechanisms
involved.
Hepatitis C virus
Chronic HCV infection is another important global
cause of HCC: 170 000 million people are currently
estimated to be chronically infected with this virus
(about 3% of the global population). The infection is
predominantly acquired in adulthood, mainly as a
result of the illicit use of intravenous drugs and trans-
fusion of contaminated blood or blood products.
Eighty per cent or more of those acutely infected
become chronic carriers, and approximately 20% of
the latter progress to cirrhosis. The annual risk of HCC
formation in those chronically infected with HCV
ranges from 8–9% in Japan to 1.9% in the United
States, and the risk is at least four times greater in those
with cirrhosis than in those without [9]. Complications
of chronic HCV infection are currently the most
frequent indication for liver transplantation in the
western world.
During recent decades, the incidence of HCV-rela-
ted HCC has increased markedly in Japan and to a
lesser extent the USA, the UK, and some western
European countries. HCV is now the major risk factor
for HCC in Japan (which has a high incidence of
HCC), Spain and Italy (with intermediate incidences),
and many industrialized countries with a low incidence
of the tumor [9]. There is a 70–80% 5-year recurrence
rate after resection of HCV-induced HCC [10].
Recurrences are more likely in those with persistent
viremia. When chronic HCV and HBV infections
occur together, the hepatocarcinogenic potentials of
the two viruses are synergistic.
HCC formation in patients with chronic HCV
infection has been thought to be the result of virally
induced necroinflammation [9]. However, more recent
evidence suggests that the virus may also be directly
carcinogenic.
Cirrhosis
All etiological forms of cirrhosis may be complicated by
the development of HCC, although not with equal
frequency [11]. The main culprits are chronic HBV
and HCV infections and alcohol abuse. Chronic HCV
infection and alcohol abuse often occur together as risk
factors in industrialized countries, but the exact nature
of their interaction remains uncertain. Apart from the
cause of the cirrhosis, increasing age and duration of
cirrhosis and male sex are the major risk factors for
malignant transformation in cirrhotic patients [11].
The increased hepatocyte turnover rate in cirrhosis acts
as a potent tumor promoter. In addition, reactive
oxygen and nitrogen species generated by the chronic
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necroinflammatory process are mutagenic and carci-
nogenic [11].
Aflatoxins
Aflatoxins are structurally related difuranocoumarin
derivatives produced mainly by certain species of
Aspergillus flavus and A. parasiticus. These molds are
ubiquitous, but because humidity and moisture
content of plants are important factors in determining
growth and toxin production by the molds, contam-
ination of crops occurs particularly in tropical and sub-
tropical countries with warm, humid climates. Certain
staple foodstuffs, such as maize, groundnuts, fermen-
ted soy beans, and soy source, are prone to contam-
ination [12–14]. Contamination takes place both
during growth of the crops and as a result of their
improper storage. Of the aflatoxins (B1, B2, G1, G2),
aflatoxin B1 (AFB1) is the one most often found in
contaminated human foodstuffs and is the most potent
hepatocarcinogen in both humans and a variety of
experimental animals [12–14]. The importance of
AFB1 as a human hepatocarcinogen is enhanced
when highs levels of dietary exposure to this toxin
occur in regions highly endemic for HBV infection.
The carcinogenic effects of the two agents are then
synergistic and multiplicative relative risks for HCC are
recorded [15].
The liver is the primary site for biotransformation of
ingested aflatoxins. The parent molecule is innocuous
but it is converted by cytochrome P450 to electrophilic
intermediates that are mutagenic [12–14]. During
phase I metabolism the parent molecule undergoes a
two electron oxidation by CYP3A4 and CYP1A2 to
form AFB1-8,9-exo-epoxide and AFB1-8,9-endo-
epoxide. AFB1-8,9-exo-epoxide is the more highly
reactive of the two. Other metabolites are formed from
AFB1, including AFQ1, AFM1, and AFP1. These are
poorer substrates for epoxidation and, consequently,
are less mutagenic than AFB1. CYP3A4 is the predom-
inant cytochrome P450 in the human liver and it forms
exo-epoxide and AFQ1, whereas CYP1A2 forms some
exo-epoxide but also a high proportion of endo-epoxide
and AFM1.
The reactive exo- and endo-epoxides are detoxified by
a number of pathways. The principal route is by
glutathione-S-transferase-mediated conjugation with
reduced glutathione to form AFB1-exo- and -endo-
epoxide-glutathione-S-transferase conjugates [12].
The exo-epoxide-glutathione-S-transferase conjugate
is converted to AFB1-mercapturic acid, which is
excreted in the urine. Both exo- and endo-epoxides can
also undergo rapid nonenzymatic hydrolysis to AFB1-
8,9-dihydrodiol [12]. If the quantity of AFB1 ingested
in the diet exceeds the capacity of the phase II pathways
to detoxify the AFB1-8,9-exo-epoxide formed or if, for
any reason, the activity of these pathways is decreased
(for example, by polymorphisms of the glutathione-
S-transferase gene), the highly reactive metabolite
accumulates and binds with high affinity to guanine
bases in cellular DNA to form the 8,9-dihydro-8-(N7-
guanyl)-9-hydroxy-AFB1 DNA (AFB1-N
7-guanine)
adduct [12]. This adduct can give rise to guanine to
thymine transversions in cellular DNA. AFB1 and
AFG1 dialdehydes do not bind to DNA but form Schiff
bases with primary amine groups (e.g. lysine), to form
protein adducts such as AFB1-albumin [12].
Iron overload
Iron overload of the liver occurs mainly in two diseases,
hereditary hemochromatosis and dietary iron overload
in the Black African (formerly called Bantu visceral
siderosis). HCC often complicates hereditary hemo-
chromatosis, and the longer the patient survives the
greater is the risk (the relative risk may be as high as
200) [16]. Cirrhosis is a very common complication of
the excess hepatic iron and was thought to be an
essential precursor of the malignant transformation.
However, in recent years about 30 patients with
hereditary hemochromatosis but without cirrhosis
have been reported to develop HCC, raising the
possibility that excess hepatic iron may be directly
carcinogenic as well as inducing HCC indirectly by
causing chronic necroinflammatory hepatic disease. In
some patients with hereditary hemochromatosis HCC
has developed after therapeutic iron depletion. This
should not discount the potential role of excess iron in
hepatocarcinogenesis. The carcinogenic effects of
chemicals may become evident only 20 or more years
after exposure, and it may be argued that the patho-
genetic mechanisms responsible for malignant trans-
formation were irreversibly under way before iron
depletion was accomplished.
Similar levels of hepatic iron may be present in
dietary iron overload in the Black African [17]. This
condition results from the consumption of large
quantities of alcoholic beverages that are brewed in
iron drums or pots and have a high iron content.
During the process of fermentation, the pH of the
ferment drops to a very low level, causing iron to leach
out of the container into the contents. Cirrhosis
accompanies iron overload in fewer of these patients
than occurs in hereditary hemochromatosis [16], but
this condition too is complicated by HCC formation,
with a relative risk of 10.6 (95% confidence limits
1.5–76.8) and a population attributable risk of 29 in
one study [18]. Support for a direct carcinogenic effect
of excess hepatic iron is provided by a recent report of
the formation of iron-free foci and HCC in the absence
of cirrhosis or portal fibrosis in an animal model
(Asare, Paterson, Kew and Mossando, unpublished
observations).
Microcystins
In most rural regions in China with a high incidence of
HCC, the population drinks primarily pond or ditch
water. Drinking water from these artificial sources or
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(to a lesser extent) river water rather than deep-well
water, is a risk factor for HCC in some of these regions;
relative risks of 1.9 (95% confidence interval 1.01–
4.74) and 2.9 (95% confidence interval 2.59–3.27)
have been recorded in Haimen and Fusui, respectively
[19]. Microcystins derived from blue-green algae have
been identified in pond and ditch water in high inci-
dence regions of HCC and differences noted in the
microcystin content of the drinking water of HCC
patients and controls [19]. In experimental studies in
rats microcystins act as a tumor promoter in aflatoxin-
induced liver cancers [20].
Prevention of hepatocellular carcinoma
Attempts to prevent HCC are of relatively recent
origin, but there is every prospect that it will eventually
be possible to prevent most cases of this common and
devastating tumor. For the immediate future the
emphasis should be on practical and economical
interventions in countries with high incidences of
HCC, especially low-income countries.
Primary prevention
Primary prevention is, at least theoretically, the most
effective form of cancer prevention. It lends itself
particularly well to intervention in viral, chemical, and
physical causes of cancer. Given that oncogenic hepa-
titis viruses contribute to the development of 75–80%
of global HCC, prevention of these chronic infections
would have a huge impact on the global occurrence of
the tumor. Primary prevention could best be accom-
plished by immunization against the viruses. This
approach became possible when an effective and safe
vaccine against HBV became available in the 1970s.
Immunization against hepatitis B virus infection in the
prevention of hepatocellular carcinoma
HBV vaccine has been incorporated into the Expanded
Program of Immunization (EPI) in 181 countries,
including most, if not all, countries in eastern and
south-eastern Asia and the Pacific islands. As a result,
80–90% of babies in these countries are now being
immunized against HBV. This accomplishment has
already resulted in a 90% to 15% decrease in the
percentage of chronically infected babies born to highly
infectious carrier mothers in these countries, and a 10-
fold or more decrease in the rate of chronic HBV
carriage in the age groups immunized [21]. Because of
the long interval between initial infection with HBV
and the development of HCC, it will take 30–50 years
for a decrease in incidence of HBV-induced HCC to be
realized in adults in these countries. Nevertheless, in
Taiwan, where immunization of babies against HBV
began in 1984 and universal coverage was achieved by
1986, the prevalence of HCC among children in the
age group that had received the vaccine has decreased
by 70% in comparison with children in the nonvacci-
nated age groups [21]. In the early reports, the decrease
was greater in boys than girls [22], but in later studies
based on a larger number of children this difference
was not evident (70% decrease in boys, 62% in girls)
[23]. These findings augur well for the eventual elim-
ination of HBV infection in that region. Unfortunately,
in sub-Saharan Africa, for a number of reasons but
mainly because of financial constraints, competing
health care priorities (HIV/AIDS, malaria, tuber-
culosis, measles, and diarrheal illnesses) and poor
delivery services not able to access large parts of the
populations, 510% of babies have until recently been
immunized against the virus. However, with the
provision of financial backing from the Global Alliance
for Vaccines and Immunization (GAVI), the Vaccine
Fund, and other governmental and nongovernmental
sources, the dismal picture in sub-Saharan Africa is
now changing for the better [24]. The extremely
encouraging results achieved in the Far East give
promise that the universal incorporation of HBV
vaccine into the EPI in all countries in this region and
in sub-Saharan Africa will prevent approximately
1 000 000 deaths per year from HCC and cirrhosis in
future birth cohorts [24], and that with universal
immunization throughout the world HCC caused by
this virus could ultimately be completely prevented.
Because of the early onset of chronic HBV infection
in highly endemic regions, immunization should be
performed shortly after birth. In populations in which
perinatal transmission from highly infectious HBV e
antigen-positive mothers to their babies predominates,
the highest level of protection against the virus (86%) is
achieved when the first dose of the vaccine is given as
soon after birth as possible together with hyperimmune
hepatitis B globulin as passive prophylaxis, followed by
the second and third doses of the vaccine at 1 and 6
months, respectively [21]. In practice, because of its
high cost, hyperimmune globulin is seldom given, and
this decreases the rate of protection by 5–10%. Active
immunization with three or four doses of vaccine
without hyperimmune globulin is immunogenic in
90% of neonates born to noncarrier mothers or
HBeAg-negative carrier mothers [21]. In regions in
which the majority of the infections that become
chronic are acquired a little later in life by the hori-
zontal route, the first dose of the vaccine is being given
slightly later and without passive immunization. Three
injections are normally given. The need for a booster
dose at the time of entering school has not yet been
resolved.
The introduction of HBV vaccine into the EPI in
most countries and the beneficial effect this has already
had in reducing viral carriage rates and the occurrence
of HCC in vaccinated children is undoubtedly the most
promising and far-reaching development in the
prevention of this tumor and indeed, indirectly, other
virally induced tumors. HBV vaccine can rightfully
claim to be the first ‘anti-cancer vaccine’. The universal
Prevention of hepatocellular carcinoma 19
inclusion of HBV vaccine in the EPI throughout the
world has already required and will continue to require
considerable investment of resources and time.
Regrettably, health workers and epidemiologists
concerned with the prevention of cancer are still largely
unaware of this momentous development in global
cancer control [24].
Immunization against hepatitis C virus in the prevention
of hepatocellular carcinoma
Despite considerable research over a number of years
into the development of a vaccine against HCV, there
appears to be little likelihood of such a vaccine
becoming available in the near future. Difficulties
impeding the development of this vaccine include the
extreme variability of the genomic structure of the
virus, especially in the hypervariable region, the large
number of quasispecies in the blood of infected indi-
viduals, and the lack of evidence for an effective
neutralizing antibody against the virus.
Other forms of primary prevention against HBV
and HCV
Because the full beneficial effects of immunization
against HBV will not be felt for many years and there is
no early prospect of a vaccine against HCV, other
methods of preventing the spread of these viruses must
continue to be rigidly enforced in an attempt to prevent
HCC induced by these viruses. These precautions are
more important in preventing HCV-related HCC
because persistent infection with this virus occurs
predominantly in adulthood as a result of intravenous
drug abuse and transfusion of contaminated blood or
blood products [25], routes that are more amenable to
prevention than those responsible for the great majority
of the chronic infections leading to HBV-induced
HCC [7,8]. In spite of recent advances in treating
HCV infection, the overall impact of therapy is rela-
tively small because the majority of chronically infected
individuals are unaware that they are infected [25].
Consequently, prevention of infection with this virus
by means other than vaccination and anti-viral treat-
ment will continue to be an important strategy for the
foreseeable future. Efforts to prevent infection should
focus on identifying persons at increased risk of HCV
infection and providing them with counselling and
testing for the presence of the virus, as well as reducing
both the incidence of new infections and the risk of
progression to chronic liver disease. The following
practices should be introduced on as wide a scale as
possible [25].
1. Safe injection practices.These are based on education
of medical, paramedical and dental practitioners to
avoid the use of unnecessary injections and to improve
the safety of injection and infusion techniques. The
latter includes rigid adherence to the use of needles and
syringes on a single occasion only or, if this is not
possible, the unfailing use of fool-proof methods of
sterilization of needles or syringes that have to be re-
used. Also important is the avoidance of, or correct use
of, multi-dose vials, and lessening the risk of noso-
comial infections resulting from needle-stick injuries
by the proper disposal of used needles and, and
whenever possible, the use of ‘disposal-proof’ needles.
Preventing HCV and HBV infections in illicit drug
users remains a difficult and sometimes contentious
issue. Changes in injection practices that will minimize
sharing of contaminated equipment by providing
‘needle and syringe exchange programs’ (which should
include exchange not only of needles and syringes but
also all the other drug paraphenalia) on as wide a scale
as is possible is a pivotal part of any program to prevent
infection spread of HCV or HBV among drug addicts.
2. Screening of donated blood for the presence of hepatitis
viruses. Transfusion-associated HCV and HBV infec-
tions have been virtually eliminated in industrialized
countries by screening all donated blood with sensitive
assays for detecting these viruses. Regrettably, screen-
ing of donated blood for blood-borne viruses is not
performed in many low-income countries. Rectifying
this hazardous practice is an essential step in prevent-
ing HCV-induced HCC and to a lesser extent HBV-
induced HCC in these countries.
3. The rational use of viral inactivation steps in the
manufacture of blood products.
4. Passive immunization. Passive immunization with
hepatitis B hyperimmune globulin is useful in
preventing transmission of HBV, but it is expensive
and its effect is of limited duration. Its use alone will
not prevent all cases of perinatal HBV infection, and
the fact that it is more expensive and less effective than
HBV vaccine precludes its use in this situation. The
value of immune globulin in preventing HCV infec-
tions has still to be ascertained.
5. Anti-viral agents. Treatment with currently used
anti-viral agents has limited efficacy in the sustained
eradication of hepatitis B and C viruses, and so does
relatively little in preventing the spread of these viruses.
Nevertheless, treatment with interferon-a (IFN-a) of
individuals chronically infected with these viruses
reduces the risk of, or delays the development of,
HCV-induced HCC and possibly HBV-induced HCC
(see Tertiary prevention, below).
Aflatoxin B1 exposure
Contamination of staple foodstuffs by AFB1 does not
occur in industrialized countries because those food-
stuffs that might be affected are screened for their
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aflatoxin content by governmental agencies and do not
enter the market if unacceptably high levels are found.
The problem occurs in low-income countries where
the crops are either consumed by the subsistence
farmer or are sold locally or regionally without ever
coming under the scrutiny of a governmental agency.
Because contamination by A. flavus or A. parasiticus
takes place both during growth of the crops and as a
result of their improper storage, attempts at primary
prevention need to be focused on minimizing both
sources of fungal contamination and AFB1 production
[12–14]. One possible intervention is to alter agri-
cultural practices in regions of high dietary AFB1
intake by replacing crops that are highly susceptible to
fungal contamination with others, such as rice, at lower
risk. This approach has been successfully used in one
limited study in China when a change to a rice-based
diet resulted in an appreciable decrease in AFB1 intake,
but for most communities in low-income countries a
change in diet is not feasible [12–14]. Relatively simple
pre-harvest prevention could involve spraying with
fungicides and, because damaged plants are more
susceptible to fungal contamination, increasing the
resistance of the plants to fungal infection by ensuring
adequate irrigation and spraying with insecticides [12–
14]. In the longer term contamination of growing crops
might be prevented by the introduction of non-afla-
toxigenic strains of Aspergillus to compete with the
aflatoxin-producing strains, or by genetically engi-
neering foodstuffs that are resistant to infection by
Aspergillus species. However, these methods may not
be affordable in countries with the greatest need to
prevent dietary exposure to AFB1.
The likelihood of contamination during storage is
increased by excessive moisture and any form of
damage to the crops. Methods of combating this
include sun-drying of the crops before storage and
drying on cloth rather than directly on the earth; well-
ventilated, rain-proof storage facilities; storage in jute
rather than plastic sacks and in wooden containers
rather than on the earth; removal of visibly moldy
plants by hand sorting; and the use of insecticides to
control insect damage and fungicides to prevent spread
of fungal spores [12,13]. A study of the effectiveness of
these preventive methods is underway in Conakry,
Guinea [26]. If these interventions are to be successful
in practice, education of subsistence farmers in their
use and the provision of financial assistance for their
institution will be required. Even so, they are unlikely
to completely eliminate contamination of stored staple
foodstuffs by AFB1.
Dietary iron overload in the African
Dietary iron overload has virtually disappeared from
urban Black African populations as a result of a change
in their drinking habits from home-brewed sorghum-
based beverages with a high iron content to commer-
cially available iron-free varieties of alcohol. However,
the pattern of alcohol consumption in rural areas
remains largely unchanged. Attempts at intervention
would require education about the health hazards of
alcohol brewed in iron drums or pots, backed up by the
provision of suitably sized aluminium or other iron-free
containers. Such a program has yet to be attempted on
a large scale.
Blue-green algae and microcystins
Since 1973 the Chinese government has been urging
the rural population to drink water from deep wells
[27]. This has resulted, for example in Qidong county,
in 80% of the population now drinking deep well-water
compared with 20% in the 1970s [27]. In addition, in
some regions the drinking water is treated by granular-
activated carbon filtration. It is too soon to assess the
effect of these interventions on the occurrence of HCC.
Secondary prevention
Secondary chemoprevention entails the use of natural
or synthetic chemicals to block, retard, or reverse the
carcinogenic process. Effective strategies need to be
safe, inexpensive, and mechanistically simple. There
are currently two etiological forms of HCC in which
preliminary evidence indicates that chemoprevention
might be possible. These are AFB1-induced and alco-
hol-induced HCC.
Chlorophyllin
The possibility of modulating the balance between
metabolic activation and detoxification of AFB1 lends
itself to chemoprevention of this cause of HCC.
Sodium copper chlorophyllin is derived from natural
chlorophylls and has been used as a food colorant and
in a number of over-the-counter medicines for
controlling odor in geriatric and osteomy patients and
as an accelerant in wound healing [14,28]. It is an
effective anti-carcinogen in a number of experimental
models [29], including AFB1-induced HCC. Chloro-
phyllin forms tight molecular complexes with a
number of chemical carcinogens, including aflatoxins,
thereby reducing their bioavailability and hence their
carcinogenic potential [30]. It also acts as an anti-
oxidant to inhibit lipid peroxidation [31]. A single
randomized, double-blind, placebo-controlled trial has
thus far been conducted in Qidong county, China [28].
This showed that 100 mg of chlorophyllin, adminis-
tered three times a day for 4 months, caused a 55%
reduction in the median level of urinary excretion
of the AFB1 DNA adduct, AFB1-N
7-guanine, when
compared with placebo. No toxic side effects were
observed and compliance to the drug was good.
Further trials are needed to ascertain whether the long-
term administration of this drug will be feasible and
safe. Supplementation of the diet with foods that are
rich in chlorophylls, such as spinach and other leafy
green vegetables, might be a more practical alternative.
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Oltipraz
A second approach is to modify the detoxification
pathway of AFB1 in such a way as to render its reactive
metabolite innocuous. The anti-schistosomal drug,
oltipraz (a substituted 1,2-dithiole-3-thione) is struc-
turally similar to the dithiolethiones found in cruci-
ferous vegetables that may play a role in cancer
prevention [14,32]. Oltipraz is a potent inducer of the
expression of the phase II detoxifying enzyme, gluta-
thione-S-transferase, and also regulates the transcrip-
tion of genes encoding other conjugating or
antioxidative enzymes, and might therefore be effective
in the secondary prevention of AFB1-induced HCC
[32]. Keap1 (Kelch-like ECH-associated factor 1)
sequesters Nrf2, a member of the nuclear factor
erythroid-derived 2 family, in the cytoplasm by binding
to its amino-terminal regulatory domain [33]. Treat-
ment with oltipraz disrupts the interaction between
KEAP1 and NRF2, allowing NRF2 to translocate to
the nucleus, where it forms heterodimers with small
MAF-family proteins to activate the expression of
glutathione-S-transferase and other genes [13]. More
recent studies of the pharmacodynamic effects of olti-
praz have shown that the drug also has an inhibitory
effect on certain phase 1 enzymes, including CYP3A4
and CYP1A2 [34]. It therefore reduces the activation
of AFB1 to AFB1-8,9-exo-epoxide. Oltipraz thus
affects the metabolism of AFB1 at two levels.
A randomized, placebo-controlled, double-blind
trial conducted in Qidong county, China, showed a
2.6-fold increase in the urinary excretion of the AFB1-
8,9-exo-epoxide metabolite, AFB1-mercapturic acid,
and lesser increases in excretion of other AFB1
biomarkers [35]. However, because of cost and safety
considerations, it is doubtful whether this drug could
be used on a wide scale in the secondary prevention of
HCC.
Polyprenoic acid
Crucial events in alcohol-induced hepatic damage are
an altered homeostasis and depletion of retinoids
(retinyl esters, retinal, and retinoic acid) [36] and the
proliferative activation of hepatocytes, changes that
may provide a promoting environment for hepato-
carcinogenesis. Malfunction of the retinoid nuclear
receptors may do likewise [36]. Possible mechanisms
for these actions may involve ‘cross-talk’ with the
alcohol-activated JNK-dependent signalling pathway
and inhibition of c-jun and c-fos activity and the
induction of apoptosis. The restoration of retinoids
and their homeostasis by either dietary supplementa-
tion or the use of an inhibitor of retinoid metabolism
might thus have a secondary preventive effect.
Polyprenoic acid, an acyclic retinoid, was originally
shown to have chemopreventive properties in experi-
mental models of liver cancer [36]. In addition, the
agent suppresses cell growth and induces differentia-
tion and apoptosis in human cancer cell lines [36]. Oral
administration of polyprenoic acid over 12 months has
been reported in a double-blind, placebo-controlled
trial in Japanese patients to delay and perhaps prevent
second HCCs after resection of the initial tumor or its
eradication using percutaneous ethanol injection, and
to significantly improve survival rate [7,38]. Serum
lactin-reactive a-fetoprotein (AFP-L3), which indi-
cates the presence of transformed hepatocytes in the
remnant liver, disappeared after 12 months of admin-
istration in the polyprenoic acid group but not in the
placebo group. This observation suggests that the
AFP-L3-producing latent malignant clones were
eliminated from the remnant liver by the polyprenoic
acid and prevented recurrence of HCC [38,39]. The
findings in this trial will need to be confirmed in further
studies with a prolonged follow-up period before its use
for this indication can be advocated.
A whole host of chemicals have been shown in
animal models or tissue culture experiments to prevent
cancer formation or to have properties that suggest that
they might have chemopreventive potential. However,
until the use of these substances can be shown to be
effective, safe and feasible in humans, they cannot be
considered to have a role in the secondary prevention of
human HCC. The same is true of a number of mole-
cular manuevers performed in transgenic animal
models, and of dietary changes in animals known to
spontaneously develop liver cancers.
Other chemoprevention possibilities
A decrease in the risk of HCC correlates with an
increased consumption of leafy green vegetables [40].
These vegetables contain a range of biologically active
phytochemicals. Plants belonging to the family Cruci-
ferae and the genus Brassica (including broccoli,
cauliflower, and Brussels sprouts) contain large quan-
tities of isothiocyanates, mostly in the form of their
glycosinolate precursors. Some of these isothiocya-
nates have been shown to inhibit tumor formation in
rats [41]. Trials of the use of glycosinolates and
isothiocyanates from broccoli sprouts in preventing
HCC in cohorts of subjects at high risk for the tumor
are in progress [13].
Hereditary hemochromatosis
Whether or not excess hepatic iron is proved to be
directly hepatocarcinogenic, ‘de-ironing’ of patients
with hereditary hemochromatosis by repeated vene-
section would be expected to have a secondary pre-
ventive effect against HCC formation both by reversing
the accumulation of iron and preventing the develop-
ment of cirrhosis. Analyses have shown that removing
the iron dramatically improves prognosis. Life expec-
tancy reverts to normal and the number of cases of
HCC decreases if cirrhosis is not present, and survival
improves considerably in those with cirrhosis [42].
‘De-ironing’ aims to lower the serum ferritin concen-
tration to a normal level and to keep it there. This
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intervention is preferably commenced as soon as the
diagnosis of hereditary hemochromatosis is made and
should be continued for life.
Tertiary prevention
Chronic necroinflammatory hepatic disease, com-
monly in the form of cirrhosis, less often chronic
hepatitis, and rarely ‘reversed lobulation’ resulting
from chronic suprahepatic portal hypertension, is a
premalignant condition [11]. The three most common
causes of chronic necroinflammatory hepatic disease
complicated by the development of HCC are HBV and
HCV infections and alcohol abuse. In the first two,
attempts have been made to prevent progression of
chronic hepatitis or cirrhosis to HCC by treating the
preneoplastic virally induced necroinflammation. IFN
has been most widely used for both HCV- and HBV-
induced diseases, and glycyrrhizin has been tried in
chronic HCV infection. These agents may be regarded
as being immunopreventive by functioning as bio-
logical response modifiers.
Use of IFN-a in preventing HCV-related HCC
HCV-related HCC is becoming an increasingly
important problem in many industrialized countries.
Its development is closely related to the duration and
progression of chronic HCV hepatitis and cirrhosis. A
large number of studies of the use of IFN treatment in
preventing the development of HCC in patients with
chronic HCV-related hepatitis or cirrhosis have now
been reported, particularly from Japan and Europe
[43]. Most, but not all, have shown that such treatment
reduces the risk of progression to HCC or delays the
development of the tumor [43]. However, many of the
published analyses, particularly the earlier ones, have
had defects in design, although some of these have
been difficult to avoid because of ethical and logistic
considerations. Particularly important among the
defects have been poor matching of treated and
untreated patients and insufficient length of patient
follow-up. It takes at least 5 years to show a statistically
significant difference between the hepatocarcinogen-
esis rate in IFN-treated and -untreated patients.
Another difficulty in proving a beneficial effect of IFN
treatment is the high rate of carcinoma development
even in the treated group.
IFN-induced prevention or delay in HCC formation
has been shown to be likely in patients with chronic
HCV hepatitis, but conflicting results have been
obtained when cirrhosis has been present. However, a
recent meta-analysis of 11 studies involving 2178
patients with HCV-related cirrhosis confirmed that
IFN significantly reduced the risk of tumor formation
[44]. The reduction in rates of malignant transforma-
tion complicating both chronic hepatitis and cirrhosis
has been far greater in patients in whom a sustained
response to IFN was obtained [45–47]. In some studies
the beneficial effect of IFN was confined to patients in
whom a sustained viral clearance was achieved,
whereas in others it also accompanied a sustained
biochemical response (normalization of serum trans-
aminase levels) [45–48]. Nevertheless, the tumor may
develop even with complete elimination of the virus
and normalization of the serum transaminase levels,
and IFN does not prevent HCC development in
nonresponders.
HCC is more likely to develop in the presence of
severe hepatic fibrosis [48]. Fibrosis has been shown
either to progress more slowly or to regress in patients
in whom IFN induces a sustained virological response
and normalization of serum transaminase levels, indi-
cating that the antifibrotic effects of IFN may contri-
bute to its chemoprevention capability [49,50].
Support for a tertiary preventive effect of IFN is
provided by studies that show that this treatment
prevents recurrences of HCC after initial resection or
ablative treatment [51,52], although further more
carefully controlled trials are needed to put the issue
beyond doubt.
The mechanism or mechanisms by which IFN
reduces the risk for HCC are uncertain. Clearance of
the virus and reduction in hepatic inflammation are
obvious factors, but another mechanism may be up-
regulating the function of tumor suppressor genes [53].
IFN is known to have a tumor inhibiting effect on HCC
cell lines [54].
The combination of pegylated IFN and ribavirin has
improved the sustained virological clearance rates in
patients with chronic HCV infection. However, the use
of this combination in the prevention of HCC devel-
opment has not yet been reported.
Use of IFN-a in preventing chronic HBV-induced HCC
In contrast to the many studies of the effect of IFN in
preventing the development of HCC in patients with
HCV-induced chronic hepatitis or cirrhosis, few
studies have addressed this issue in patients with HBV-
related disease and the findings have been conflicting.
Most studies have failed to provide convincing
evidence that treating patients with HBV-related
cirrhosis or chronic hepatitis with IFN will lessen the
risk of malignant transformation. A recent meta-
analysis of the available literature showed that consis-
tent results were observed only with studies emanating
from European countries and these did not indicate a
protective effect of IFN [55]. Chronic HBV carriers
with low serum HBV DNA levels seldom progress to
tumor formation [56]. Those with very high levels may
prove to the ones in whom IFN does protect against the
development of HCC.
Glycyrrhizin
Glycyrrhizin, the active principle of licorice, has a
chemical structure similar to cortisone. It is composed
of one molecule of glycyrretinic acid and two molecules
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of glucuronic acid. Glycyrrhizin enhances IFN-g
production, has immune-modulating activity, stimu-
lates natural killer cells, and suppresses hepatic
inflammation [57,58]. The compound also has anti-
oxidative properties. It has been used for over 30 years
in Japan, partly in the form of the Chinese herbal
medicine, Sho-saiko-to, of which glycyrrhizin is one of
the main ingredients, in the treatment of chronic
hepatitis (by far the most common cause of which is
HCV). Daily injections of glycyrrhizin reduce the levels
of the serum aminotransferases in a dose-dependent
manner in these patients, although antiviral activity
per se is not evident [59]. In a prospective trial
performed in Japan over 15–20 years, a 2.5-fold lower
risk of developing HCC was reported in patients who
received parenteral glycyrrhizin compared with those
who did not [59]. HCV-RNA titers did not decrease,
and the beneficial effect of the drug was attributed to
controlling or retarding necroinflammatory and fibro-
tic processes in the liver. These conclusions were
supported by two further studies [60,61]. In addition,
glycyrrhizin reduced the risk of HCC recurrence after
surgical resection [62].
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